ESMO Guidelines Endorse Lutetium Therapy; New Data on PSMA Prediction, DOAC Safety
Jun 01, 2026
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.